Retinal Disease
8 videos · last 6 months shuffled daily, then older videos newest first
▶
8:52 Full Interview with Dr. Shannon Boye from Atsena Therapeutics
Dr. Shannon Boye, Founder and Chief Scientific Officer at Atsena Therapeutics, on her background and the company's two ongoing clinical trials, recorded at the Visions 2026 conference.
▶
56:34 Luxa's RPE Stem Cell Therapy: Phase 1 Trial in AMD
Dr. Jeffrey Stern, co-founder of the Neural Stem Cell Institute and co-CEO of Luxa Biotechnology, discusses its stem cell-derived RPE therapy, early results from a first-in-human Phase 1 trial in late-stage AMD and plans to include inherited retinal disease.
▶
40:08 Stevie Ringel of Nome on AI in Ultra-Rare Drug Development
Stevie Ringel, co-founder of Nome and founder of the Kizuna Foundation, tells The Genetics Podcast how AI agents handle the operational work of small-batch ultra-rare drug development, and discusses FDA signals and funding models.
▶
15:25 Optogenetics for Treating Inherited Retinal Degenerations
Retina Synthesis discusses Phase 2 results from Nanoscope regarding the use of optogenetics for treatment of retinal degenerations with Allen Ho, MD, Professor of Ophthalmology, Wills Eye Hospital.
▶
10:42 Interview with Dr. Mark Pennesi of the Retina Foundation - Visions 2026 Conference
Dr. Mark Pennesi of the Retina Foundation, an inherited retinal degeneration specialist who both treats patients and runs trials, interviewed at the Visions 2026 conference.
▶
3:21 BRILLIANCE: CRISPR Gene Editing Trial for Inherited Blindness
Mass Eye and Ear reports results from the BRILLIANCE trial of an experimental CRISPR-based gene editing medicine for a form of Leber congenital amaurosis, which was safe and led to measurable improvements in 11 participants.
▶
1:32:14 Eye on the Future Forum Fall 2020 Summit
A ProQR Therapeutics summit on Leber congenital amaurosis and sepofarsen, the RNA therapy the company is developing for LCA10.
▶
12:56 OCT-based Endpoints in Clinical Trials in Intermediate AMD – Robyn Guymer
Robyn Guymer on OCT-based endpoints in trials of intermediate age-related macular degeneration, at the International SPECTRALIS Symposium.